Business Wire

CA-ANDERSEN-GLOBAL

13.7.2024 16:43:35 CEST | Business Wire | Pressemeddelelse

Del
Andersen Global forstærker sin afrikanske platform og tilføjer værdiansættelseskapacitet i Nigeria og Sydafrika

Andersen Global har tilføjet værdiansættelseskapacitet i Afrika og styrket sin overordnede regionale dækning ved at tilknytte ​​to nye samarbejdsvirksomheder – Nelson Thorpe Alonge i Nigeria og Valeo Capital i Sydafrika. Med disse tilføjelser markerer Andersen sine første udbud af værdiansættelsesservice i Afrika og og øger dermed virksomhedens udbud af global værdiansættelse i Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.

Nelson Thorpe Alonge udbyder en komplet portefølje af værdiansættelse af aktiver, der dækker jord og bygninger, anlæg og udstyr, maritime aktiver, olie og gas, luftfart, ejendomsinvesteringer, ejendomsmæglervirksomhed, salg og opkøb, ejendoms- og facilitetsadministration samt rådgivning om ejendomsudstykning. Under ledelse af seniorpartner Victor Alonge betjener virksomheden selskaber, internationale agenturer, diplomatiske enheder, stater, statslige agenturer og personer med stor nettoformue.

"Kundernes succes og tilfredshed står i centrum af vores forretningsstrategi," siger Victor. "Vores samarbejde med Andersen Global er en milepæl for vores virksomhed og viser, at vi altid engagerer os maksimalt i forhold til vores kunder, når vi udvider vores virkeområde til at levere perfekte og omfattende værdiansættelsesløsninger globalt."

Valeo Capital er stiftet af de to partnere Riaan van Heerden og David Tosi og er en specialiseret virksomhed, der arbejder tæt sammen med kunder lige fra greenfieldvirksomheder til børsnoterede selskaber. Virksomheden yder omfattende virksomhedsfinansiering og -rådgivning, herunder fusioner og opkøb, BEE-ejerskabsstrukturering (black economic empowerment), værdiansættelse af virksomheder, due diligence og kapitalrejsning.

"Vi er stolte af den ressourcestyrke, pålidelighed og professionelle indsigt, vi giver til kunder og ønsker at fortsætte med at udvide vores udbud til kunder lokalt og globalt," siger Riaan. "Vores samarbejde med Andersen Global er en yderligere styrkelse af vores teams engagement i at yde klassens bedste service og fastholder vores konkurrencefordel i regionen."

Global Chairman og CEO for Andersen Mark L. Vorsatz siger: "Nelson Thorpe Alonge og Valeo Capital har konsekvent demonstreret deres forpligtelse på god forvaltning og kundeservice, og har skilt sig ud som førende på markedet. Både Nigeria og Sydafrika er som altid vigtige markeder, og virksomhedernes ekspertise er vigtig for vores globale ekspansionsstrategi og for at opfylde de skiftende værdiansættelseskrav fra kunder både regionalt og i udlandet."

Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skattejurister samt skatte- og værdiansættelseseksperter i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 17.000 eksperter i hele verden og en tilstedeværelse på over 475 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240711008688/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye